Research Papers:

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma

Zhen Zhang, Fan-Fan Li, Ming-Dian Lu, Shang-Xin Zhang and Yong-Xiang Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:103283-103289. https://doi.org/10.18632/oncotarget.22464

Metrics: PDF 1643 views  |   HTML 1745 views  |   ?  


Zhen Zhang1, Fan-Fan Li2, Ming-Dian Lu1, Shang-Xin Zhang1 and Yong-Xiang Li1

1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China

2Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

Correspondence to:

Yong-Xiang Li, email: [email protected]

Keywords: NY-ESO-1; antibody; intrahepatic cholangiocarcinoma; prognosis

Received: May 23, 2017     Accepted: October 28, 2017     Published: November 15, 2017


Anti-NY-ESO-1 antibody is observed in a multitude of malignancies. This study was aimed to evaluate the expression of serum anti-NY-ESO-1 antibodies and its prognostic value in intrahepatic cholangiocarcinoma. A total of 103 patients with intrahepatic cholangiocarcinoma were enrolled in the study. Enzyme-linked immunosorbent assay (ELISA) was performed to detect the serum level of anti-NY-ESO-1 antibody. Western blotting was performed to assess the NY-ESO-1 expression in tumor and adjacent tissues. The serum NY-ESO-1 antibody was detected in 18.4% of patients with intrahepatic cholangiocarcinoma, a value that was significantly higher than that in patients with chronic Hepatitis B. Serum NY-ESO-1 antibody was positively correlated with tumor differentiation, lymphatic metastasis, cTNM stage and abdominal pain. Finally, there was a higher cumulative survival rate in patients with serum NY-ESO-1 positivity than in those with serum NY-ESO-1 negativity among the patients with stage III + IV. Our data uncovered that NY-ESO-1 antibody might be a helpful tumor marker and prognostic predictor in intrahepatic cholangiocarcinoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22464